AI-generated from publicly available materials.Neopharma Technologies has recently achieved ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System, marking a significant advancement for its NEOVAULT® diagnostics platform.
This certification signifies that Neopharma's NEOVAULT® and myNEO® software solutions meet international standards for the governance and responsible management of artificial intelligence throughout their lifecycle. It complements existing certifications, such as ISO/IEC 27001 and HIPAA, enhancing Neopharma's commitment to security, privacy, and compliance in healthcare technology.
Shaun Melville, the Executive Director, emphasized that this certification is crucial for the global development of NEOVAULT®, underscoring the importance of AI governance alongside technological capabilities. Gajenddra Raj, the Chief Technology Officer, added that the ISO standard's comprehensive scope ensures that AI systems are managed with security and accountability throughout their lifecycle.
NEOVAULT® is a versatile platform designed to integrate various diagnostic technologies and workflows securely. While it currently focuses on workplace health and drug testing, its architecture is poised for future expansion into broader health diagnostics, reflecting Neopharma's strategic vision for the evolving landscape of healthcare technology.